RT Book, Section
A1 Wahl, Kimberly
A1 Schuna, Arthur A.
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1165174144
T1 Rheumatoid Arthritis
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1165174144
RD 2023/12/11
AB Content  UpdateAugust  19,  2019  Upadacitinib  (Rinvoq)  Approved  for  Treatment  of  Rheumatoid  Arthritis:  In  August  2019,  the  U.S.  Food  and  Drug  Administration  approved  upadacitinib  as  the  third  oral  janus  kinase  (JAK)  inhibitor  for  treatment  of  rheumatoid  arthritis.  Upadacitinib  15  mg  orally  once  daily  is  indicated  for  adults  with  moderately-to-severely  active  rheumatoid  arthritis  who  are  intolerant  or  not  responding  adequately  to  methotrexate.  It  may  be  used  alone  or  in  combination  with  methotrexate  or  other  nonbiologic  DMARDs.  It  should  not  be  used  with  other  JAK  inhibitors  (tofacitinib,  baricitinib),  biologic  DMARDs,  or  other  potent  immunosuppressives  (eg,  azathioprine,  cyclosporine).